No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 8 of the 34 quarters in the window, leaving 26 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.8x · 10Y median 5.4x · 41st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 35
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:52:37.838Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Nutex Health, Inc. (NUTX) stock was $222.02 as of Oct 6, 2026, 1:50 PM EDT, down 1.33% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +107.8% · 3-year avg +97.4%/yr · 5-year avg -19.0%/yr
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division.
Medical - Care Facilities · Houston, TX
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 17, 2026
42 days away
EPS Estimate
5.71
Revenue Est.
$214.98M
Last Quarter Results
EPS
$9.38
vs Estimate
$4.95
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NUTX | $1.53B | $222.02 | -1.33% | +107.84% | -18.99% | -27.99% | N/A |
| 2QURE | $1.53B | $22.05 | -3.30% | -58.31% | -6.16% | +11.17% | vs NUTX |
| 3STOK | $1.53B | $23.78 | -6.08% | -0.93% | -0.24% | N/A | vs NUTX |
| 4SNDX | $1.54B | $17.33 | -2.78% | +14.22% | -0.01% | +1.04% | vs NUTX |
| 5INVA | $1.54B | $20.89 | +1.24% | +17.98% | +4.52% | +6.43% | vs NUTX |
| 6ETON | $1.50B | $54.72 | -1.62% | +177.71% | +63.04% | N/A | vs NUTX |
3.87
$210.75M
vs Estimate
$215.03M
Consensus Rating
Based on 5 analysts
Average Price Target
$288.20
+29.8% upside
Low
$200.00
Current
$222.02
High
$325.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $5.61 | $5.71 | $5.86 | 3 |
| Quarter ending Dec 2026 | $6.11 | $6.21 | $6.38 | 3 |
| Quarter ending Mar 2027 | $7.21 | $7.33 | $7.53 | 1 |
| Quarter ending Jun 2027 | $6.65 | $6.77 | $6.95 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $27.43 | $27.79 | $28.33 | 3 |
| FY 2027 | $27.51 | $27.87 | $28.41 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $212.19M | $214.98M | $219.50M | 3 |
| Quarter ending Dec 2026 | $226.79M | $229.78M | $234.60M | 3 |
| Quarter ending Mar 2027 | $233.00M | $236.07M | $241.02M | 1 |
| Quarter ending Jun 2027 | $230.61M | $233.65M | $238.55M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $863.22M | $872.02M | $884.84M | 3 |
| FY 2027 | $954.48M | $964.20M | $978.38M | 3 |
